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ABSTRACT
Background: Hereditary diffuse gastric carcinomas
(HDGCs) are particularly troubling because of autosomal
dominant heritance, high penetrance, early age of onset,
and a lack of effective treatment once symptomatic.
HDGC is further complicated by difficulty of effective
screening. Gastrectomy provides definitive treatment for
CDH1 mutation-positive patients. Attempting to minimize
the morbidity and mortality of this procedure via a lapa-
roscopic approach is appropriate.
Methods: Six consanguineous patients, 21 to 51 years of
age, were identified as carriers of the CDH1 gene muta-
tion. All of the patients’ gastric mucosa was normal by
endoscopic appearance and biopsy. After appropriate
multispecialty counseling, all patients elected to undergo
a laparoscopic total gastrectomy. Demographics, geneal-
ogy, operative approach, outcomes, and pathology were
reviewed.
Results: All gastrectomies were completed using a laparo-
scopic approach. Gross examination of resected stomachs
was unremarkable. Histological examination demonstrated
multiple foci of invasive signet ring adenocarcinoma in all
patients. There were no anastomotic leaks, one small bowel
obstruction requiring reoperation, and one esophageal stric-
ture requiring dilation.
Conclusions: This series demonstrates the utility and
safety of the laparoscopic approach for prophylactic total
gastrectomy for carriers of the CDH1 gene mutation. It
serves to highlight that patients with CDH1 mutations may
be more likely to undergo gastrectomy if they are offered
the lower risk laparoscopic approach.
Key Words: Total laparoscopic gastrectomy.
INTRODUCTION
An estimated 21,130 new cases of gastric cancer occurred
in the United States in 2009, and this represents a decrease
in incidence.1 This decline was accompanied by a de-
crease in mortality; however, it is unlikely that familial
gastric cancers share similar fortunes. Hereditary Diffuse
Gastric Cancers (HDGCs) represent 1% to 3% of all gastric
cancers, and of those, up to 53% can be attributed to
mutations in the CDH1 gene.2–4 These familial cancers
demonstrate autosomal dominant heritance and high pen-
etrance. The 5-year survival is 20% if the diagnosis is
made after the patient is symptomatic.5 This is com-
pounded by the lack of reliable screening for early stage
resectable tumors.6
Heuristics like the number and age of onset for family
clusters of diffuse gastric cancer can identify those patients
at highest risk, and testing of affected individuals and
relatives can identify the presence of CDH1 mutations.
After appropriate counseling, asymptomatic members of
that family can then be screened for a CDH1 mutation. For
patients with a CDH1 mutation of unknown significance,
or in familial gastric cancer without an identifiable CDH1
mutation, the literature does not support any recommen-
dations at this time. For patients with an identified CDH1
mutation, prophylactic surgery is a logical solution.
However, it is estimated that the risk of fatal HDGC ex-
ceeds the approximate 1% mortality risk of a gastrectomy
for patients over 20 years of age.6 Physicians should
present to patients the strong evidence supporting pro-
phylactic gastrectomies and help them understand the
range of surgical and nonsurgical options available.
Knowledge that a laparoscopic gastrectomy can minimize
the morbidity and mortality associated with the surgery
may help ease the decision-making process.
METHODS
This is a case series of 6 consanguineous patients identi-
fied as carriers of the CDH1 gene mutation. After appro-
priate multispecialty counseling, all patients elected to
undergo a laparoscopic total gastrectomy. After Institu-
tional Review Board approval, demographics, genealogy,
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SCIENTIFIC PAPERoperative approach, outcomes, and pathology were re-
viewed.
RESULTS
Demographics
The series comprised 6 patients, 3 males and 3 females.
The age range was 21 to 51 years old with an average of
38.2 years. All patients had their surgeries performed at
the Karmanos Cancer Institute of Detroit, by a team of
minimally invasive surgeons. All of the patients were res-
idents of the state of Michigan at the time of their surger-
ies.
Genealogy
The patients were suspected of having hereditary gastric
cancer when 2 relatives died of gastric cancer in their early
thirties. The disease affected 2 separate generations of the
family with the first affected family member (individual
II-5, Figure 1) dying of gastric cancer at age 32. Individual
II-5 had 5 siblings, 4 of whom were alive and could be
tested. Three of the 4 agreed to genetic testing and were
found to carry a CDH1 mutation. Individual II-4 was not
tested, and her CDH1 status is currently unknown. She has
2 young girls, ages 11 and 8, who also have not been
tested. Several children of the 3 CDH1 positive siblings
(II-1, II-2, II-6) have been tested and have been found to
carry the CDH1 gene (III-4, III-9, III-10). The CDH1 status
of the remaining family members is unknown. Individual
III-1 died in her early thirties, and although her CDH1
status was unknown, given her age, disease course, and
the presence of the mutation in her mother, it is highly
likely that she was CDH1 positive. Of the family members
known to have undergone genetic testing, 6 of 6 have
tested positive for the CDH1 mutation. It is presumed that
the 2 who died prior to testing indeed also carried the
gene defect.
Surgery
All patients were asymptomatic at the time of their testing
and surgery and had no abnormal abdominal findings on
physical examination. All patients had genetic counseling
prior to testing and surgery. All patients were screened
endoscopically and were free of any gross gastric disease.
Random gastric biopsies were performed in all cases. The
biopsies were unremarkable.
All patients underwent a laparoscopic Roux-en-Y esoph-
agojejunostomy. In all cases, the Roux limb was brought
up to the esophagus in a retrocolic orientation. The
esophageal anastomosis was performed with an Orvil
(25-mm, 3.5-mm Covidien, Norwalk, CT) that was passed
transorally. The jejunojejunostomy was performed with a
linear stapler (EndoUniversal GIA, Covidien). All hernia-
site defects were closed including Peterson’s defect, the
jejunal mesentery, and the mesocolic window. A drain
was left near the site of the esophagojejunostomy and was
removed before the patient was discharge from hospital.
No intraoperative endoscopy was used to test the integrity
of the anastomosis, and no radiologic leak tests were
performed postoperatively. All cases were done using 5
ports, 4 of which were 5-mm ports (Figure 2). A fifth
12-mm port placed in the left anterior axillary line at the
Figure 1. Family genealogy of hereditary gastric cancer.
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was extended at the end of the case to extract the stomach
via an endocatch appliance.
Operative time ranged from 287 minutes to 372 minutes
with an average time of 292 minutes. The mean length of
stay (LOS) was 7.8 days (median 5 days, range 3 to 23).
Postoperatively, the patients were placed on regular sur-
gical wards and advanced in diet starting with clear liq-
uids. All patients were seen back in the clinic and were
found to be doing well.
One patient developed a stricture at the esophageal anas-
tomosis that was treated successfully by endoscopic bal-
loon dilatation. One patient developed nausea and vom-
iting on postoperative day 5 and was subsequently
diagnosed with a small bowel obstruction secondary to
adhesions around the mesocolic window. Operative re-
pair, including lysis of adhesions and revision of the me-
socolic window, was completed on postoperative day 10.
The jejunojejunostomy anastomosis appeared healthy and
was without leaks at the time of reoperation. Subse-
quently, the patient developed a hydropneumothorax,
drained once by ultrasound-guided aspiration and once
by CT-guided aspiration. The remainder of the hospital
course was uncomplicated, and this patient was dis-
charged on hospital day 23.
Pathology
All of the stomachs were examined after removal from the
body and were found to be grossly normal. Microscopic
examination of the specimens showed that each had mul-
tiple microscopic foci of invasive signet ring cell carci-
noma. The mean number of foci was 8.2 (median 4, range
2 to 19). The number of foci was reported for 5 of 6
patients; the sixth patient was noted to have multiple foci
but no count was provided by the pathologist. All of the
foci of invasive carcinoma were confined to the lamina
propria, and the largest focus noted was 0.5cm. All of the
lymph nodes were negative. The mean lymph node har-
vest was 12.3 (median 10.5, range 5 to 25). All patients
were staged as pT1N0MX.
DISCUSSION
Prophylactic gastrectomy in HDGC is a definitive treat-
ment. Patients with a CDH1 mutation have a 70% to 80%
risk of developing DGC over their lifetime, and the 5-year
survival for symptomatic DGC is 20%. Genetic counsel-
ing and genetic testing are mandatory before offering a
prophylactic total gastrectomy to any patient. Families
suspected of possessing a CDH1 gene mutation should be
screened by using the modified criteria as proposed by
Suriano et al,7 and genetic testing can be offered to ap-
propriate patients. In those found to carry a CDH1 muta-
tion, prophylactic gastrectomy is advised.
Because of incomplete penetrance, some 20% to 30% of
CDH1 mutation carriers will not develop DGC. Screening
techniques, while contributing to the decline in overall
gastric cancer mortality, are insufficient for early DGC,
because of its tendency to underlie normal gastric mu-
cosa. Two modalities, PET-CT and chromo-endoscopy
have shown some potential for identifying early stage
DGC, but both have limitations that prevent them from
being implemented as an alternative to prophylactic gas-
trectomies.6
Total gastrectomy is not without complications. Overall,
the 30-day mortality for total gastrectomy ranges from 3%
to 6%.8 This is not surprising considering that gastrecto-
mies are usually performed in older, sicker patients. In
younger, healthier populations undergoing total gastrec-
tomy, such as those with HDGC, morbidity and mortality
has been estimated to be in the 1% to 2% range.9 One
recent retrospective study of laparoscopic-assisted total
gastrectomy patients (not specifically HDGC) showed no
perioperative mortality among 131 patients and a postop-
erative morbidity rate of 19%.10 Postoperative complica-
tions included a range from ileus (2.3%) to anastomotic
leak requiring reoperation (0.8%), with the most common
being wound complications (5.3%). Even these results
may overestimate perioperative morbidity for prophylac-
tic gastrectomies, as complications were not reported by
tumor stage, and 24 patients (18%) were TNM stage II or
greater.
Long-term morbidity after total gastrectomy includes al-
terations in eating habits, dumping syndrome, diarrhea
Figure 2. Trocar location for laparoscopic gastrectomy.
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method. There is typically a 10% to 15% decrease in body
weight, which is principally body fat. Dumping syndrome
occurs in 20% to 30% of patients but tends to improve with
time.11 Overall, laparoscopic gastrectomies have demon-
strated decreased perioperative morbidity and mortality
over open12; patients had early return of bowel function,
tolerated oral intake early, and were discharged earlier
than those undergoing open procedures. The patients in
this study were on average started on clear liquid diets by
postoperative day 5.8 (median 4, range 2 to 20) and had
an average LOS of 7.8 days as previously noted. This is in
comparison with open gastrectomies where the average
length of stay ranged from 10 days to 18 days.13,14 Earlier
discharge and less morbidity may be significant factors in
patients’ decision to have a laparoscopic prophylactic
gastrectomy.
The patients in this series selected the surgeon for his
prior work in performing a hand-assisted laparoscopic
total gastrectomy, which was reported as the first laparo-
scopic-assisted gastrectomy for HDGC.15 There is at least
one additional report of prophylactic laparoscopic gas-
trectomies for CDH1 mutation carriers.16 Most literature
comments on the dilemma of incomplete penetrance
when prophylactic gastrectomies are offered to CDH1
positive patients. What is less clear is whether the out-
comes of previously reported prophylactic surgeries have
been discussed. Over 92% of prophylactic surgeries re-
ported in the literature have shown one or more foci of
signet ring cell adenocarcinoma.17 This makes these sur-
geries curative, rather than prophylactic. Considering the
expected 5-year survival difference, the distinction be-
tween curative (in T1N0M0) and prophylactic surgeries
may be irrelevant, though no data have been published to
support this conclusion. However, the semantics may
help patients decide. Being cured of cancer is arguably a
more powerful motivator for surgery than is prevention of
cancer by that same surgery. That does raise the issue of
oncologic staging. When performed as prophylaxis, there
is little concern for oncologic staging, because there is no
cancer to stage. When surgery is therapeutic, staging be-
comes an issue. In the past, laparoscopic total gastrectomy
has been criticized, because doubts remain concerning its
ability to satisfy oncologic staging criteria met during more
conventional open surgery. In general, most CDH1 posi-
tive patients undergoing a therapeutic (nee prophylactic)
gastrectomy have early carcinoma, either in-situ or con-
fined to the lamina propria. Guidelines given by the In-
ternational Gastric Cancer Linkage Consortium (IGCLC)
indicate that it is essential to document the complete
removal of gastric mucosa by histologically identifying
esophageal and duodenal mucosa at the 2 ends of the
surgical specimen.9 Additionally, the American Joint Com-
mittee on Cancer (AJCC) recommends that at least 15
lymph nodes be examined for staging purposes, but does
allow for pN0 staging to be based on examination of
resected nodes.18 Multiple studies of gastric cancer have
indicated that for early stages of disease, the laparoscopic
approach allows appropriate resection of gastric tissue and
adequate harvest of D1 lymph nodes.19 Extension to D2
lymph nodes for early stage cancer presented additional risk
without significantly altering the 5-year survival.20 There is
no reason to believe these results cannot be extrapolated to
early DGC.
CONCLUSION
Minimally invasive surgery is playing an increasing role in
the management of disease. This is highlighted in our case
series, where we demonstrate the utility and safety of the
laparoscopic approach toward prophylactic total gastrec-
tomy in a family with HDGC. All of the patients in this
series treated with gastrectomy demonstrated microscopic
foci of invasive adenocarcinoma with no evidence of local
or distant spread. Thus, these surgeries were curative,
rather than prophylactic.
While current screening techniques are inadequate to
make the distinction between prophylactic and curative
surgery for these early stage patients, pre- and periop-
erative patient counseling should highlight the realities
inherent in the data. Laparoscopic total gastrectomy not
only provides a cure, but also satisfies oncologic stag-
ing requirements and provides for quicker recovery and
decreased morbidity. We feel it is well suited for asymp-
tomatic CDH1 positive patients in HDGC families. This
recommendation comes with screening by family his-
tory, genetic counseling, consultation with a multi-spe-
cialty team, and the recommendation that the surgery
should only be performed by a surgeon experienced in
performing laparoscopic total gastrectomies. Moreover,
this series demonstrates that gastrectomies can be per-
formed successfully utilizing a laparoscopic approach
minimizing morbidity compared with open gastrecto-
mies. We believe that the laparoscopic approach should
be offered as first-line therapy to CDH1-positive pa-
tients.
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